Last reviewed · How we verify
Biotinylated Red Blood Cells — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Biotinylated Red Blood Cells (Biotinylated Red Blood Cells) — John A Widness.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Biotinylated Red Blood Cells TARGET | Biotinylated Red Blood Cells | John A Widness | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Biotinylated Red Blood Cells CI watch — RSS
- Biotinylated Red Blood Cells CI watch — Atom
- Biotinylated Red Blood Cells CI watch — JSON
- Biotinylated Red Blood Cells alone — RSS
Cite this brief
Drug Landscape (2026). Biotinylated Red Blood Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/biotinylated-red-blood-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab